Summary We report for the first time the frequency distributions of HLA-DRB1 and -DQB1 genes in 55 patients with testicular germ cell carcinoma (TGC) using the modified PCR-RFLP method and compare the results with those for 1216 healthy Japanese control subjects. The modified PCR-RFLP method produced accurate, reproducible cleavage patterns that are easily discriminated. HLA-DRB1*0410 was the susceptibility allele (RR = 3.26, P = 0.006) and DQB1 *0602 appears to be a candidate protective allele (RR = 0.26, P = 0.02) for TGC in the Japanese. None of the HLA-DRB1 and -DQB1 alleles showed a specific tendency for histological type or clinical stage of the tumours. Previous studies based on serotyping methods failed to show these allelic associations. High-resolution genotyping is essential because the peptide-binding domain of MHC class 11 molecules is determined more precisely by their genotypes than by their serotypes. In addition, inherent technical difficulties and typing errors of up to 25% make serotyping inefficient. Our results suggest that high-resolution genotyping is a useful genetic marker to determine risk for TGC.
Testicular germ cell carcinoma (TGC), although relatively rare in the male population in general, is the most common malignancy in men between the ages of 15 and 35 years. Strong evidence for the involvement of genetic factors has been reported in TGC development. The incidence of TGC in first degree relatives is 2.2%, and in unrelated individuals 0.4%. For an individual who has a father or brother with TGC, the relative risk of developing TGC is increased sixfold compared with men in the general population. The concordance of tumour histology is high in twins and low in father-son pairs (Tolerud et al, 1985) . Moreover, the incidence of TGC is relatively high among white American men in comparison with black American or Oriental men living in the same geographical areas (Senturia, 1987) . Finally, as a pluripotential, polymorphic and commonly heterogeneous cancer, TGC is markedly affected by the host environment, e.g. when a murine embryonal carcinoma cell is placed in a mouse blastocyte, it may differentiate in an orderly fashion and participate in the creation of a normal mouse (Richie, 1992) . All this evidence suggests that HLA association could be one of the genetic factors in the development of TGC.
Previous studies (DeWolf et al, 1979; Pollack et al, 1982; Oliver et al, 1986; Aiginger et al, 1987; Kratzig et al, 1989) on the association of HLA antigens with TGC have shown no association with the HLA-A and HLA-C regions, and inconsistent association with the HLA-B region. Despite the inherent technical limitations of conventional methods used for HLA-DR typing, such as cytotoxicity, previous studies have claimed a consistent association of TGC with HLA-DR antigens. Some of these studies have suggested the need for genotyping (Oliver et al, 1986; Yoshimura Reports published up to 1982 did not include HLA-DR. Later studies included the DR region, but the number of antigens determined was limited (Pollack et al, 1982) . This means that, up to now, there has been no complete HLA-DRB 1 typing, even by serotyping. The purpose of our molecular epidemiological study was to identify high-risk individuals, thereby allowing for their close surveillance and the early detection of these potentially curable tumours.
MATERIALS AND METHODS
Patients and controls Fifty-five Japanese patients with TGC confirmed histopathologically were obtained for study from the 1990-96 tumour registries at Kyoto University Hospital and its affiliated hospitals without any selection criteria. The histological diagnosis and clinical stage were based, respectively, on the modified WHO classification system (Mostofi and Sobin, 1977) and the tumour-nodesmetastasis staging systems (UICC, 1989) . The clinicopathological profiles of the patients are given in Table 1 . As controls, we used the genetic frequencies of HLA-DRB 1 and -DQB 1 in 1216 healthy Japanese subjects reported at the 11th Japanese HLA Genotyping Workshop held by the Japanese Society for Histocompatibility and Immunogenetics in 1994 (Akaza et al, 1994) .
DNA extraction and PCR-RFLP High molecular weight genomic DNA was extracted from the patients' peripheral blood lymphocytes after proteinase K digestion by the standard phenol-chloroform method (Perucho et al, 1981) . The modified PCR-RFLP method for HLA-DRB1 genotyping described by Ota et al (1992) and that for HLA-DQB1 described by Nomura et al (1991) were used. Briefly, the polymorphic exon 2 (-) controls. An RR value less than than 0.5 was assigned as relatively low risk, and an RR value more than 2 was assigned as relatively high risk. We performed significance tests only for those alleles with relatively low risk or relatively high risk. P-values were corrected by the number of comparisons made in the overall study. The 5-value was estimated according to Thompson (1981) . Values of the preventive fractions (PFc, PF) and aetiological fractions (EFc, EF) were estimated according to Green (1982) .
RESULTS
The modified PCR-RFLP method produced accurate, reproducible, and easily discriminative cleavage patterns of highresolution HLA-DRB1 and DQB1 genotyping (Fig. 1) . The distribution of the HLA-DRB 1 and DQB 1 genotypes together with the When more than one allele shows an association with a particular disease, the appropriate measure for determining which allele has the strongest association with the disease is the 6-value. The 6-value for the susceptibility allele DRBI *0410 was 4.63, and for the relatively protective allele DQBI *0602 was 0.85. The preventive fractions (PFc, PF) demonstrate that, among individuals who carry DQBI *0602, this allele is highly protective. In the general male population, expression of the DRBI *0410 allele causes the highest susceptibility, and this allele is the allele most significantly associated with TGC tumours.
Genotyping of testicular germ cell carcinoma 1351 The associations of DRBI *0403 and DQBI *0302 with seminoma and low-stage tumours were not significant (P > 0.05). There was no specific association between the other DRBI and DQBI alleles and histological type or clinical stage of the tumours. The clinicopathological data collected in our study were taken from first admission information, which may be the reason for the discrepancy. In fact, the status of both TGC patients who carried the protective allele DQBI *0602, one with initial stage pT2NOMO seminoma and one with stage pT3N4M1 embryonal cell carcinoma, showed no evidence of disease after 5 years of survival.
DISCUSSION
HLA-DRBI *0410 showed a highly significant association with susceptibility to TGC, and DQBI *0602 appeared to protect against TGC development. The validity of the latter statement, however, needs to be confirmed. Previous studies (DeWolf et al, 1979; Pollack et al, 1982; Oliver et al, 1986; Aiginger et al, 1987; Kratzig et al, 1989 ) that used conventional methods, such as microcytotoxicity, failed to show this allelic association. High-resolution genotyping is essential because the polymorphism of the peptidebinding domain of MHC class II molecules is more precisely determined by genotypes than by serotypes. The HLA-DRBI and -DQBI genes are extremely polymorphic, and the amino acids they encode are located in regions that line the sides and floor of the peptidebinding groove, which is related to immune responsiveness as well as to the ability to bind antigenic peptide and to be recognized by CD4 T-cell receptors (Rukstalis et al, 1989; Nomura et al, 1991; Ota et al, 1992; Ayala, 1995; Futami et al, 1995) .
Despite the difficulties inherent in conventional HLA-typing methods, on the basis of NIH microcytotoxicity findings DeWolf et al (1979) reported that HLA-A, and -B antigens were not associated with TGC and that Drw7 was more frequent in teratocarcinoma (RR = 8.32). Pollack et al (1982) , who typed 145 white American males with TGC tumours, found no association with HLA-C antigens, but reported a high frequency of DR5 in pure seminoma cases. Aiginger et al (1987) , who typed 66 patients with TGC, have reported a high frequency of DR5 antigen with metastasis. Oliver et al (1986) have reported increased DR5 antigen and decreased DR3 antigen frequencies in seminoma. In 1989, Kratzig et al pooled all the previous data with their results on HLA typing for TGC and reported a significantly increased frequency of DR5 in seminoma and some association of HLA-B 13 with nonseminomatous germ cell tumours. These previously reported findings are adequate for MHC class I typing but not for class II typing. In fact, none of the reports up to 1982 included HLA-DR and, although later studies included the DR region, the number of antigens determined was limited (Pollack et al, 1982) . With regard to the serotype frequencies found in our study, DR5 was slightly more frequent in TGC patients than in the control subjects (12.72 vs 8.10) and showed a greater tendency for semonima. DR3 and DR7 are very infrequent in the Japanese population (0.12% and 0.25% respectively). The inconsistency in the reports on the association of some of HLA-B antigens with TGC tumours may stem from the strong linkage between the HLA-B and HLA-DRB I regions. The weaker antigenicity of HLA-A than HLA-B reported in organ transplants, despite the antigens' structural similarities, is attributed mainly to the weak association of HLA-A with HLA-DR, whereas HLA-B has a strong association with HLA-DR (Tiercy et al, 1991; Ichikawa et al, 1993) .
The strong influence of MHC complex genes on the development of diseases with a mainly autoimmune background has been reported. The demonstration of the major role of mouse MHC (H-2) in determining resistance to the development of murine leukaemia led to a number of studies. Two tumour types, Hodgkin's disease and nasopharyngeal carcinoma, have consistently been reported to be significantly associated with HLA antigens in both unrelated and familial studies (DeWolf et al, 1979; Oliver et al, 1986; Senturia, 1987) .
Theoretically, cancer may arise under conditions of genetic or acquired reduced immune capacity. In patients undergoing organ transplants, a significant overall two-to five-fold increased risk of TGC tumours has been reported. This confirms that an impaired immune system allows carcinogenic factors to act. The worldwide epidemic of acquired immunodeficiency syndrome (AIDS) provides further evidence of the effect of and risk of specific cancers. Serotyping analyses showed that the development of Kaposi's sarcoma in patients with full-blown AIDS was strongly associated with HLA-DR5 (Pollack and Livingstone, 1985; Smeraldi et al, 1986; Birkeland et al, 1995) .
An MHC class II allele, DQBI *0301, has been shown to be significantly linked to the incidence of melanoma and advanced disease status (Lee et al, 1994) , indicative of the association of cancer development with MHC class II genes. Our findings that HLA-DRBI *0101 and *0405 are protective alleles in patients with renal cell carcinoma (Ozdemir et al, 1997 ) is well established, with spontaneous regression of the RCC in some patients. The association of cervical carcinoma and MHC class II genes is still a matter of dispute, mainly owing to typing difficulties as stated (Glew et al, 1992) . In addition, because a greater number of class II genes have been detected by genomic analysis than by serology, new standards for bone marrow and other organ transplants have been established (Tiercy et al, 1991; Ichikawa et al, 1993) .
In conclusion, genotyping of MHC class II genes promises to provide useful information for early tumour detection and for predicting the prognosis of patients with various malignancies.
